Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting

Rhea-AI Summary

Calidi Biotherapeutics (NYSE American: CLDI) will hold an investor event at the 2025 Society of Immunotherapy for Cancer (SITC) Annual Meeting on Friday, November 7, 2025 from 8:30 AM to 9:30 AM in National Harbor Room 15 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

The presentation will focus on the company’s RedTail platform and lead candidate CLD-401, feature members of Calidi’s scientific advisory board and leadership, and will be live streamed at https://vimeo.com/event/5482626/8149f00207.

Calidi said it is conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug (IND) application by end of 2026; the company is also pursuing strategic partnerships to accelerate development.

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced that it will hold an investor event at the Society of Immunotherapy for Cancer (SITC) Annual Meeting centered around the Company’s groundbreaking RedTail platform and its lead candidate, CLD-401.

The presentation will take place at the SITC Annual Meeting on Friday, November 7^th from 8:30AM to 9:30AM in the National Harbor Room 15 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

The presentation will also be live streamed: (https://vimeo.com/event/5482626/8149f00207).

Speakers at the event will include:

• Dr. Dmitriy Zamarin of the Icahn Genomics Institute and the Precision Immunology Institute at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Dr. Zamarin is a world renowned expert in virotherapy. Dr. Zamarin is a member of Calidi’s Scientific Advisory Board (SAB).
• Dr. Antonio F. Santidrian, Chief Scientific Officer of Calidi, responsible for leading all of the Company’s research and development initiatives.
• Dr. John M. Wrangle, a thoracis medical oncologist at the Medical University of South Carolina (MUSC).  Dr Wrangle is an expert on the clinical development of IL-15 superagonist. Dr. Wrangle is also a member of Calidi’s SAB.
• Dr. Travis Clifton, Chief Medical Officer of Calidi and a surgical oncologist with over 17 years of experience in drug development, early phase and translational clinical trials, and cancer immunotherapy.

“We are excited to hold our first investor event,” said Eric Poma, PhD, Chief Executive Officer. “We believe CLD-401 and the RedTail platform represent important breakthroughs in the area of genetic medicine, and we look forward to updating the investment community on our progress.”

Calidi is currently conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug (IND) application by the end of 2026. The company is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.

About Calidi 

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.

CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need.

Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.

Forward-Looking Statements

This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 31, 2025, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

For Investors:

Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
CLDI@redchip.com 

FAQ

When and where is Calidi Biotherapeutics (CLDI) presenting at SITC 2025?

Calidi will present on November 7, 2025 from 8:30 AM–9:30 AM in National Harbor Room 15 at the Gaylord National Hotel, National Harbor, Maryland.

How can investors watch Calidi (CLDI) if they cannot attend SITC in person?

The event will be live streamed at https://vimeo.com/event/5482626/8149f00207.

What topics will Calidi (CLDI) cover at the investor event on November 7, 2025?

The presentation will focus on the RedTail platform and lead candidate CLD-401, including scientific and clinical development updates.

Who are the key speakers for Calidi’s (CLDI) SITC investor event?

Speakers include Dr. Dmitriy Zamarin, Dr. Antonio F. Santidrian, Dr. John M. Wrangle, and Dr. Travis Clifton, plus company leadership.

What is the clinical development timeline for Calidi’s CLD-401 (CLDI)?

Calidi is conducting IND-enabling studies for CLD-401 and expects to submit an IND application by the end of 2026.

Is Calidi (CLDI) seeking partnerships to advance the RedTail platform?

Yes, the company said it is actively pursuing strategic partnerships to accelerate clinical development and broaden RedTail’s impact.